Remove Medical Imaging Remove Pharmaceutical Remove Radiopharmaceuticals
article thumbnail

The Transformative Impact of Radiopharmaceuticals in Medical Imaging

Open Medscience

Radiopharmaceuticals, combining radioactive and pharmaceutical elements, enable precise diagnosis and treatment in nuclear medicine. The post The Transformative Impact of Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.

article thumbnail

Interview: Helen Blanco talks about innovation in oncology space

Keosys Medical Imaging

With her large experience in the pharmaceutical industry, Helen Blanco currently serves as Chief Operating Officer at Node Pharma , a preclinical radiopharmaceutical company based in Norway. We recently spoke with Helen about the key criteria when selecting an imaging vendor and exciting upcoming innovations in the oncology space.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

Imaging Technology

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

article thumbnail

Interview: Focus on the Scandinavian pharmaceutical market

Keosys Medical Imaging

With her large experience in the pharmaceutical industry, Helen Blanco currently serves as Chief Operating Officer at Node Pharma , a preclinical radiopharmaceutical company based in Norway. Here is another excerpt from our conversation.

article thumbnail

NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies

Imaging Technology

He has more than 22 years of operational and commercial expertise in radioisotopes and radiopharmaceuticals. actinium-225 (Ac-225), and drive business development initiatives for NorthStar’s Radiopharmaceutical CDMO/CMO business units. Ac-225 and Cu-67 using environmentally preferable technologies. SPECT franchise.

article thumbnail

NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer

Imaging Technology

milla1cf Mon, 06/19/2023 - 19:27 June 19, 2023 — NorthStar Medical Technologies, LLC , a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D.,

Medical 98
article thumbnail

NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production

Imaging Technology

BWXT Medical will collaborate closely with NorthStar, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, to streamline production processes, enhance safety protocols and innovate new methods of isotope generation.

Medical 105